文献速递血管炎

体细胞TET2突变与巨细胞动脉炎的关联

Association of Somatic TET2 Mutations With Giant Cell Arteritis.
PubMed 文献 · Arthritis Rheumatol · 2024-02-02

研究利用英国生物银行470,960名参与者的外显子测序分析克隆性造血与巨细胞动脉炎(GCA)的关联,并对本机构114例GCA患者进行靶向测序和病历回顾。克隆性造血者发生GCA的风险增加1.48倍,TET2突变者风险最高(HR 2.02),TET2突变与GCA相关视力丧失相关(OR 4.33)。

要点

  • 克隆性造血与GCA发病风险增加相关(风险增加1.48倍)。
  • TET2突变者GCA风险最高(HR 2.02,P=0.00116)。
  • TET2突变与GCA患者视力丧失相关(OR 4.33,P=0.047)。

核心结论

  • 克隆性造血以基因型特异性方式增加GCA发病风险,其中TET2突变 confer 的风险最大。
  • 体细胞TET2突变同样增加GCA相关视力丧失的风险。
  • 未来可能有必要将体细胞基因检测整合到GCA诊断中。

研究设计与样本

  • 研究分析了470,960名英国生物银行参与者的外显子测序数据以检测克隆性造血,并使用多变量Cox回归分析其与GCA的关联。
  • 对本机构114例GCA患者进行血液样本靶向测序和电子健康记录回顾,以分析克隆性造血至血液系统恶性肿瘤谱系中体细胞突变与GCA临床表型的关联。

主要发现

  • 英国生物银行中,有克隆性造血的参与者发生GCA的风险是无克隆性造血参与者的1.48倍。
  • GCA风险在伴有血细胞减少的个体中最高(HR 2.98,P=0.00178),在伴有TET2突变的个体中次之(HR 2.02,P=0.00116)。
  • 本机构GCA队列中27.2%的患者检测到突变,其中3例在GCA诊断时患有血液系统恶性肿瘤。
  • TET2突变与GCA患者视力丧失相关(OR 4.33,P=0.047)。

关键数值与推荐

  • 克隆性造血与GCA发病风险增加相关(风险增加1.48倍)。
  • 血细胞减少者GCA风险HR 2.98(P=0.00178),TET2突变者GCA风险HR 2.02(P=0.00116)。
  • 本机构GCA队列突变检出率27.2%,其中3例在GCA诊断时伴有血液系统恶性肿瘤。
  • TET2突变与GCA患者视力丧失相关,OR 4.33(P=0.047)。

临床怎么用

  • 未来可能有必要将体细胞基因检测整合到GCA诊断中。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Giant cell arteritis (GCA) is an age-related vasculitis. Prior studies have identified an association between GCA and hematologic malignancies (HMs). How the presence of somatic mutations that drive the development of HMs, or clonal hematopoiesis (CH), may influence clinical outcomes in GCA is not well understood. METHODS: To examine an association between CH and GCA, we analyzed sequenced exomes of 470,960 UK Biobank (UKB) participants for the presence of CH and used multivariable Cox regression. To examine the clinical phenotype of GCA in patients with and without somatic mutations across the spectrum of CH to HM, we performed targeted sequencing of blood samples and electronic health record review on 114 patients with GCA seen at our institution. We then examined associations between specific clonal mutations and GCA disease manifestations. RESULTS: UKB participants with CH had a 1.48-fold increased risk of incident GCA compared to UKB participants without CH. GCA risk was highest among individuals with cytopenia (hazard ratio [HR] 2.98, P = 0.00178) and with TET2 mutation (HR 2.02, P = 0.00116). Mutations were detected in 27.2% of our institutional GCA cohort, three of whom had HM at GCA diagnosis. TET2 mutations were associated with vision loss in patients with GCA (odds ratio 4.33, P = 0.047). CONCLUSIONS: CH increases risk for development of GCA in a genotype-specific manner, with the greatest risk being conferred by the presence of mutations in TET2. Somatic TET2 mutations likewise increase the risk of GCA-associated vision loss. Integration of somatic genetic testing in GCA diagnostics may be warranted in the future.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Robinette ML, Weeks LD, Kramer RJ, et al. Association of Somatic TET2 Mutations With Giant Cell Arteritis. Arthritis Rheumatol. 2024. PMID: 37909388. doi:10.1002/art.42738

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。